Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 7/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.77 |
| ▸ | PGR | P06401 | 4/20 | 0.77 |
| ▸ | AR | P10275 | 3/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | APEX1 | P27695 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone SCHEMBL5037570 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL7755941 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL18762039 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL13046625 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL8809468 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL3183 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL7614763 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL5486743 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL5037573 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA | |
| Beclomethasone SCHEMBL5486747 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4NR3C1NFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226116-A1 | Glucocorticoid Particles and Their Use | CRITITECH, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11931368-B2 | Glucocorticoid “nintedanib” particles and their use | CRITITECH, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4281051-A1 | VESICLES AND USES THEREOF | Exocure Sweden AB (SE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230107561-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3980784-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210187081-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200399628-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020247625-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (GB) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020243261-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200246355-A1 | Glucocorticoid Particles and Their Use | CRITITECH, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20180289776-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTIINFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170258927-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-2494075-A2 | TEMPLATED NANOCONJUGATES | Northwestern University (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2473160-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | Northwestern University (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011053940-A2 | TEMPLATED NANOCONJUGATES | NORTHWESTERN UNIVERSITY (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011028850-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | NORTHWESTERN UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | HIF1A 4422/4885CYP3A4 3964/4885NR3C1 3/4885 |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | HAVCR2, CCL5, IRF3 | HIF1A 3484/4885CYP3A4 3719/4885NR3C1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.